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Abstract
We analyzed the effect of the N factor on prognosis of T3C ovarian cancer patients who underwent optimal
surgery (OpS). According to the analyses of N factor in OpS group, prognosis was poor in N1 group, however
prognosis was signiﬁcantly better in the complete group than in the other group with residual tumor of less
than 1 cm.
Introduction: The primary debulking surgery that is performed to achieve complete debulking is one of the most
important prognostic factors in patients with advanced ovarian cancer. However, the relationship between lymph node
metastases and the surgical outcome is still unclear. This study analyzed the effect of the N factor on the prognosis of
patients with pT3C ovarian cancer who underwent optimal surgery (OpS). Patients and Methods: The participants
were 68 patients with pT3C serous adenocarcinoma. The overall survival (OS) and the median survival time (MST) were
analyzed by the diameter of the residual tumor and by lymph node metastasis using the Kaplan-Meier method and the
log-rank test. The patients received retroperitoneal lymph node dissection in the pelvic cavity up to the para-aortic
lymph nodes. The patients in the OpS group were further divided into a complete-surgery group with no residual
tumor and a group with residual tumor of less than 1 cm, and differences were analyzed. Results: The OS rates in the
OpS group and Sub-OpS group were 77.5% and 11.1%, respectively. According to the analyses made by different
levels of lymph node metastasis in all patients, the OS rates in patients with N0 and N1 disease were 77.1% and
47.5%, respectively; the prognosis was signiﬁcantly poorer in the N1 group. According to the analyses of the N factor
in the OpS group, the prognosis was signiﬁcantly poorer in the N1 group even with OpS compared with that in the N0
group (53.7% and 86.6%, respectively). Furthermore, in the N1 group with OpS, the prognosis was signiﬁcantly better
in the complete-surgery group than in the other group with residual tumor of less than 1 cm (77.8% and 16.7%,
respectively). Conclusion: The prognosis of pT3CpN1 ovarian cancer with OpS was as poor as with Sub-OpS.
However, the results suggested that the prognosis could be improved if the tumor was completely resected in OpS.
Clinical Ovarian and Other Gynecologic Cancer, Vol. 6, No. 1/2, 36-41 ª 2014 Elsevier Inc. All rights reserved.
Keywords: Debulking surgery, Lymph node metastasis, Optimal surgery, Ovarian cancer, PrognosisIntroduction
Ovarian cancer has the highest mortality of all female repro-
ductive cancers. The most important prognostic factor for patients
with ovarian cancer is the stage, and patients with stage III or IV
disease have poor prognosis. Early ovarian cancer may not cause any
symptoms, and ovarian cancer stage distribution at diagnosis shows
that more than half of patients with ovarian cancer are diagnosed at
an advanced stage (III or IV).1 Thus, the major problem in ovarianDepartment of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan
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Clinical Ovarian and Other Gynecologic Cancer December 2013cancer treatment is to improve the prognosis in patients with
advanced-stage disease. First-line treatment in ovarian cancer is
surgery, which requires maximal debulking surgery as well as
identiﬁcation of the histologic type and proper surgical staging of
the tumor. Especially in patients with advanced-stage disease, re-
sidual tumor diameter can be a vital prognostic factor after surgery.
Many studies have reported that the smaller the diameter of the
residual tumor, the better the prognosis.2-5 Although surgical
reduction with residual disease less than 1 cm is optimal surgery
(OpS), achievement of complete surgery (CS) without residual disease
can improve the prognosis in patients with advanced-stage
disease. Therefore, in principle, primary debulking surgery (PDS)
should target CS as a goal. However, the relationship between residual
tumor diameter and prognosis in cases associated with metastasis to
retroperitoneal lymph nodes has not been clariﬁed. This study2212-9553/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.06.006
investigated the relationship between the outcome of maximal
debulking surgery and lymph node metastasis in patients with pT3C.
Patients and Methods
A total of 68 patients with pT3C serous adenocarcinoma
(including serous papillary adenocarcinoma) who were treated in the
authors’ facility were enrolled in this study. PDS was performed in
all patients without neoadjuvant chemotherapy. Retroperitoneal
lymphadenectomy meant lymph node dissection extending from
the pelvic lymph nodes to the para-aortic lymph nodes at the height
of the renal veins. After PDS, all patients were treated with post-
operative combined chemotherapy with paclitaxel/carboplatin.
Overall survival (OS) and median survival time (MST) were
analyzed by using the Kaplan-Meier method and the log-rank test,
dividing the OpS group into a CS group and a group with residual
tumor of less than 1 cm.
Results
Of 68 patients, 59 (86.8%) received OpS; the other 9 (13.2%)
received Sub-OpS. There were 47 patients in the OpS group who
had no residual tumor (CS group), and 12 patients had residual
tumor less than 1 cm. Of 68 patients, 20 (29.4%) had retroperi-
toneal lymph node metastasis (N-positive group).
The MST of patients in the OpS group was not detected, and the
5-year OS was 77.51%. In the Sub-OpS group, the MST was 589
days, and the 5-year OS was 11.11%. Thus, the prognosis was
signiﬁcantly better in the OpS group (P < .001) (Figure 1).
The MST of patients in the CS group was not detected, and the
5-year OS was 85.31%. The MST of patients with residual tumor
less than 1 cm was 1390 days, and the 5-year OS was 47.62%. The
prognosis was signiﬁcantly better in the CS group (P ¼ .0014)
(Figure 2).
In the N-negative group, the MST was not detected, and the
5-year OS was 77.15%. In the N-positive group, the MST wasFigure 1 Kaplan-Meier Analysis of Overall Survival: Optimal Surger
Abbreviation: MST ¼ median survival time.1390 days, and the 5-year OS was 47.5%. The prognosis was
signiﬁcantly better in the N-negative group (P ¼ .0194) (Figure 3).
In the 59 patients of the OpS group, 16 (27.1%) were N-positive
and 43 (72.9%) were N-negative. In the OpS/N-negative group,
the MST was not detected, and the 5-year OS was 86.59%. In the
OpS/N-positive group, the MST was not detected, and the 5-year
OS was 53.57%. Thus, the prognosis was signiﬁcantly better in
the OpS/N-negative group (P ¼ .0064) (Figure 4).
In the 20patients of theN-positive group, 16 (80.0%) receivedOpS
and 4 (20.0%) received Sub-OpS. In the OpS/N-positive group, the
MST was not detected, and the 5-year OS was 53.57%. In the Sub-
OpS/N-positive group, the MST was 589 days, and the 5-year OS
was 25.0%.Therewas no signiﬁcant difference (P¼ .1388) (Figure 5).
In the 16 patients of the OpS/N-positive group, 10 (62.5%) were
in the CS group and 6 (37.5%) had residual disease less than 1 cm.
In the OpS/N-positive/CS group, the MST was not detected, and
the 5-year OS was 77.78%. In the group with OpS/N-positive and
with residual disease less than 1 cm, the MST was 910 days, and the
5-year OS was 16.6%. The prognosis was signiﬁcantly better in the
OpS/N-positive/CS group (P ¼ .0074) (Figure 6).
The prognosis in the OpS/N-positive/CS group was signiﬁcantly
better compared with the group with OpS/N-positive and with
residual tumor less than 1 cm and compared with the Sub-OpS/N-
positive group (P ¼ .0074 and P ¼ .0170, respectively). However,
there was no signiﬁcant difference between the group with OpS/N-
positive and with residual tumor less than 1 cm and the Sub-OpS/
N-positive group (P ¼ .9339) (Figure 7).
Discussion
The diagnostic role of retroperitoneal lymphadenectomy in sur-
gery for ovarian cancer is established as the means to identify the
precise stage, but its therapeutic role is not established. Regarding
early-stage ovarian cancer, a retrospective study of the outcomes of
6686 patients with clinical stage I found that the prognosis wasy Versus Suboptimal Surgery
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Figure 2 Kaplan-Meier Analysis of Overall Survival: Complete Surgery Versus Less-Than-1-cm Surgery
Abbreviation: MST ¼ median survival time.
Effect of N Factor on Prognosis
38 -signiﬁcantly better in those with retroperitoneal lymphadenectomy
than in those without retroperitoneal lymphadenectomy.6 In a
randomized comparative study with or without retroperitoneal
lymphadenectomy in patients with early-stage disease, a clear
conclusion was not provided because of the small number of
patients.7
Regarding advanced ovarian cancer, in a randomized comparison
study dividing patients with stage pTIIIb-pTIV disease into a
“systematic retroperitoneal lymphadenectomy group” and a “bulky
nodes resection alone group,” progression-free survival (PFS) was
signiﬁcantly better, but there was no signiﬁcant difference in OS.8Figure 3 Kaplan-Meier Analysis of Overall Survival: Retroperitoneal
Abbreviation: MST ¼ median survival time.
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nectomy improved PFS in patients who underwent OpS.9
The role of retroperitoneal lymphadenectomy in advanced cases
is different from the role in early cases. Its diagnostic role regarding
stage decision is not signiﬁcant. In terms of a therapeutic role with a
contribution to prognostic improvement, surgical removal of bulky
lymph nodes as an organ, based on the concept of maximal
debulking surgery, is meaningful considering achievement of CS.
The point in controversy is whether retroperitoneal lymphadenec-
tomy should be performed in advanced ovarian cancer cases without
macroscopically apparent metastasis or palpable metastasis.Lymph Node Metastasis, Positive Versus Negative
Figure 4 Kaplan-Meier Analysis of Overall Survival in Patients With Optimal Surgery: Retroperitoneal Lymph Node Metastasis, Positive
Versus Negative
Abbreviation: MST ¼ median survival time.
Fumitoshi Terauchi et alAdvanced cases require initial postoperative chemotherapy as soon
as possible, so one should consider omission or reduction of retro-
peritoneal lymphadenectomy, which can be highly invasive. On the
other hand, because potential lymph node metastasis or future
recurrence in lymph nodes (or both) are very likely in advanced cases,
the idea to conduct retroperitoneal lymphadenectomy as a prophy-
lactic measure is a persuasive strategy. To clarify this issue, the present
authors retrospectively examined the relationship between the
diameter of the residual tumor and the prognosis with retroperitoneal
lymph node metastasis. To eliminate any bias from differentFigure 5 Kaplan-Meier Analysis of Overall Survival in Patients With R
Versus Suboptimal Surgery
Abbreviation: MST ¼ median survival time.histologic types in the effects of chemotherapy, the examination was
restricted to only the serous type. Also, the International Federation
of Gynecology and Obstetrics (FIGO) stage was standardized as
pT3C for the analysis.
First, just as many reports have said, the prognosis of the OpS
group was signiﬁcantly better than that of the Sub-OpS group.
Similarly, in the OpS group, the prognosis of the CS group was
signiﬁcantly better than the prognosis of the less-than-1-cm group.
Moreover, despite the outcome of maximal debulking surgery, the
prognosis was signiﬁcantly poorer in the N-positive group than inetroperitoneal Lymph Node Metastasis Positive: Optimal Surgery
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Figure 6 Kaplan-Meier Analysis of Overall Survival in Patients With Retroperitoneal Lymph Node Metastasis Positive: Complete
Surgery Versus Less-Than-1-cm Surgery
Abbreviation: MST ¼ median survival time.
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40 -the N-negative group. Similarly, when limiting the comparison to
the OpS group only, the prognosis of the OpS/N-negative group
was better than that of the OpS/N-positive group.
However, when limiting the comparison to the N-positive group
only, despite the outcome of maximal debulking surgery, there was
no signiﬁcant difference between OpS and Sub-OpS. Upon division
of the OpS/N-positive group into a CS group and a less-than-1-cm
group, the prognosis was signiﬁcantly better in the OpS/N-positive/
CS group than in the OpS/N-positive/less-than-1-cm group. OnFigure 7 Kaplan-Meier Analysis of Overall Survival in Patients With
Surgery Versus Less-Than-1-cm Surgery Versus Suboptim
Abbreviation: MST ¼ median survival time.
Clinical Ovarian and Other Gynecologic Cancer December 2013the other hand, there was no signiﬁcant difference between the
OpS/N-positive/less-than-1-cm group and the Sub-OpS/N-positive
group.
Contrary to previous reports, the analysis that divided the OpS
group into a CS group and a less-than-1-cm group found improve-
ment of the prognosis not only in PFS but also in OS. However, even
if the outcome of maximal debulking surgery was OpS, when lymph
node metastasis was considered, there was no difference in prognosis
between the less-than-1-cm group and the Sub-OpS group.Retroperitoneal Lymph Node Metastasis Positive: Complete
al Surgery
Fumitoshi Terauchi et alConclusion
Although the prognosis of advanced ovarian cancer with lymph
node metastasis is poor, improvement of its prognosis can be
expected by aiming for CS with maximal debulking surgery as
conventional policy. On the other hand, when maximal debulking
surgery has not been able to achieve CS, a change to the strategy of
early postoperative chemotherapy with omission of retroperitoneal
lymphadenectomy should be considered; but with regard to this
point, further studies are necessary.Clinical Practice Points
 The prognosis of pT3CpN1 ovarian cancer with OpS was as
poor as with Sub-OpS. However, the results of this study sug-
gested that the prognosis could be improved if the tumor was
completely resected in OpS.
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